Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary

Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer

(2009) Mary E.R. OʼBrien   ANTI-CANCER DRUGS

Ixabepilone

(2009) Marit D. Moen   DRUGS

Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines

(2009) Maureen E. Trudeau et al.   JOURNAL OF CLINICAL ONCOLOGY

Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study

(2009) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of Ixabepilone

(2009) J. T. Hunt   MOLECULAR CANCER THERAPEUTICS

A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study

(2008) B. A. Burtness et al.   ANNALS OF ONCOLOGY

A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma

(2008) Owen A. O’Connor et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment

(2008) Eva S. Thomas   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer

(2008) Gabriella Ferrandina et al.   JOURNAL OF CLINICAL ONCOLOGY